Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Ozempic and Wegovy users are four times more likely to experience nail detachment, a new multinational study finds. GLP-1 users also reported higher rates of hair loss and scalp inflammation — and weight loss alone doesn't seem to fully explain it. Researchers say the findings call for awareness, not alarm, and urge patients to flag symptoms to their doctor rather than stop treatment.
A large multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 found that people taking GLP-1 receptor agonists — drugs like Ozempic, Wegovy, and Mounjaro — were significantly more likely to experience nail detachment, discoloration, hair loss, and scalp inflammation compared to those who had never used the medications. The study compared 575 GLP-1 users with 1,329 controls who had obesity and/or type 2 diabetes but no GLP-1 exposure.
Crucially, the differences persisted even when researchers limited the analysis to participants who had lost weight, suggesting the drug itself — not just rapid weight reduction — may play a role. Scalp inflammation accompanied most cases of hair loss, pointing to a possible inflammatory mechanism beyond the classic shedding seen with caloric restriction. That said, roughly half of GLP-1 users reported nail problems before starting treatment, and experts caution the cross-sectional design cannot establish causation.
By the Numbers:
Why it matters: With millions of patients on GLP-1 drugs, dermatological side effects are increasingly relevant for clinicians across specialties. Experts recommend proactively asking about nail and hair health at visits — and reassuring patients that these changes are usually benign and not a reason to discontinue an otherwise effective therapy.
